Selecting controls is not selecting "normals": Design and analysis issues for studying the etiology of polycystic ovary syndrome

Fertility and Sterility

Volumn 86, Issue 1, 2006, Pages 1-12

  Bloom, Michael S ^a   Schisterman, Enrique F ^a   Hediger, Mary L ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Bias; case control study; collider stratification; methods; odds ratio; PCOS; polycystic ovary syndrome; prevalence

Indexed keywords

CASE CONTROL STUDY; CONSENSUS; HUMAN; HYPOTHESIS; METHODOLOGY; OVARY POLYCYSTIC DISEASE; POPULATION RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATA INTERPRETATION, STATISTICAL; EPIDEMIOLOGIC RESEARCH DESIGN; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME; REFERENCE VALUES; RISK ASSESSMENT;

EID: 33745514680     PISSN: 00150282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fertnstert.2005.09.066     Document Type: Review

References (86)

1. Carmina E., and Lobo R.A. Polycystic ovary syndrome (PCOS). arguably the most common endocrinopathy is associated with significant morbidity in women. J Clin Endocrinol Metab 84 (1999) 1897-1899
2. Balen A., and Michelmore K. What is polycystic ovary syndrome? Are national views important?. Hum Reprod 17 (2002) 2219-2227
3. Balen A. The pathophysiology of polycystic ovary syndrome. trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol 18 (2004) 685-706
4. Hull M.G. Epidemiology of infertility and polycystic ovarian disease. endocrinological and demographic studies. Gynecol Endocrinol 1 (1987) 235-245
5. Goldzieher J.W., and Green J. The polycystic ovary. I. Clinical and histologic features. J Clin Endocrinol Metab 22 (1962) 325-338
6. Infertility. In: Beers M.H., and Berkow R. (Eds). The Merck manual of diagnosis and therapy (1999), Merck Research Laboratories, Whitehouse Station, NJ 1991-1995
7. Speroff L., Glass R.H., and Kase N.G. Clinical gynecologic endocrinology and infertility (1994), Williams & Wilkins, Baltimore, MD
8. Govind A., Obhrai M.S., and Clayton R.N. Polycystic ovaries are inherited as an autosomal dominant trait. analysis of 29 polycystic ovary syndrome and 10 control families. J Clin Endocrinol Metab 84 (1999) 38-43
9. Legro R.S., Driscoll D., Strauss III J.F., Fox J., and Dunaif A. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA 95 (1998) 14956-14960
10. Lunde O., Magnus P., Sandvik L., and Hoglo S. Familial clustering in the polycystic ovarian syndrome. Gynecol Obstet Invest 28 (1989) 23-30
11. Escobar-Morreale H.F., Luque-Ramirez M., and San Millan J.L. The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome. Endocr Rev 26 (2005) 251-282
12. Dahlgren E., Janson P.O., Johansson S., Lapidus L., and Oden A. Polycystic ovary syndrome and risk for myocardial infarction. Evaluated from a risk factor model based on a prospective population study of women. Acta Obstet Gynecol Scand 71 (1992) 599-604
13. Nestler J.E., Clore J.N., and Blackard W.G. The central role of obesity (hyperinsulinemia) in the pathogenesis of the polycystic ovary syndrome. Am J Obstet Gynecol 161 (1989) 1095-1097
14. Dunaif A. Insulin resistance and the polycystic ovary syndrome. mechanism and implications for pathogenesis. Endocr Rev 18 (1997) 774-800
15. Dunaif A., Segal K.R., Futterweit W., and Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 38 (1989) 1165-1174
16. Kiddy D.S., Hamilton-Fairley D., Bush A., Short F., Anyaoku V., Reed M.J., et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 36 (1992) 105-111
17. Wright C.E., Zborowski J.V., Talbott E.O., McHugh-Pemu K., and Youk A. Dietary intake, physical activity, and obesity in women with polycystic ovary syndrome. Int J Obes Relat Metab Disord 28 (2004) 1026-1032
18. Barker D.J. In utero programming of chronic disease. Clin Sci (Lond) 95 (1998) 115-128
19. Franks S. Adult polycystic ovary syndrome begins in childhood. Best Pract Res Clin Endocrinol Metab 16 (2002) 263-272
20. Abbott D.H., Dumesic D.A., and Franks S. Developmental origin of polycystic ovary syndrome-a hypothesis. J Endocrinol 174 (2002) 1-5
21. Venkatesan A.M., Dunaif A., and Corbould A. Insulin resistance in polycystic ovary syndrome. progress and paradoxes. Recent Prog Horm Res 56 (2001) 295-308
22. Dunaif A., Xia J., Book C.B., Schenker E., and Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96 (1995) 801-810
23. Mikkonen K., Vainionpaa L.K., Pakarinen A.J., Knip M., Jarvela I.Y., Tapanainen J.S., et al. Long-term reproductive endocrine health in young women with epilepsy during puberty. Neurology 62 (2004) 445-450
24. Isojarvi J.I., Tauboll E., Pakarinen A.J., van Parys J., Rattya J., Harbo H.F., et al. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med 111 (2001) 290-296
25. Isojarvi J.I., and Tapanainen J.S. Valproate, hyperandrogenism, and polycystic ovaries. a report of 3 cases. Arch Neurol 57 (2000) 1064-1068
26. Isojarvi J.I., Laatikainen T.J., Pakarinen A.J., Juntunen K.T., and Myllyla V.V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 329 (1993) 1383-1388
27. Bauer J., Jarre A., Klingmuller D., and Elger C.E. Polycystic ovary syndrome in patients with focal epilepsy. a study in 93 women. Epilepsy Res 41 (2000) 163-167
28. Murialdo G., Galimberti C.A., Magri F., Sampaolo P., Copello F., Gianelli M.V., et al. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 20 (1997) 519-526
29. Murialdo G., Galimberti C.A., Gianelli M.V., Rollero A., Polleri A., Copello F., et al. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 21 (1998) 52-58
30. Rasgon N.L., Altshuler L.L., Gudeman D., Burt V.K., Tanavoli S., Hendrick V., et al. Medication status and polycystic ovary syndrome in women with bipolar disorder. a preliminary report. J Clin Psychiatry 61 (2000) 173-178
31. Balen A.H., Tan S.L., MacDougall J., and Jacobs H.S. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin. Hum Reprod 8 (1993) 959-964
32. Bjercke S., Dale P.O., Tanbo T., Storeng R., Ertzeid G., and Abyholm T. Impact of insulin resistance on pregnancy complications and outcome in women with polycystic ovary syndrome. Gynecol Obstet Invest 54 (2002) 94-98
33. Weerakiet S., Srisombut C., Rojanasakul A., Panburana P., Thakkinstian A., and Herabutya Y. Prevalence of gestational diabetes mellitus and pregnancy outcomes in Asian women with polycystic ovary syndrome. Gynecol Endocrinol 19 (2004) 134-140
34. de Vries M.J., Dekker G.A., and Schoemaker J. Higher risk of preeclampsia in the polycystic ovary syndrome. A case control study. Eur J Obstet Gynecol Reprod Biol 76 (1998) 91-95
35. Diamant Y.Z., Rimon E., and Evron S. High incidence of preeclamptic toxemia in patients with polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 14 (1982) 199-204
36. Radon P.A., McMahon M.J., and Meyer W.R. Impaired glucose tolerance in pregnant women with polycystic ovary syndrome. Obstet Gynecol 94 (1999) 194-197
37. Turhan N.O., Seckin N.C., Aybar F., and Inegol I. Assessment of glucose tolerance and pregnancy outcome of polycystic ovary patients. Int J Gynaecol Obstet 81 (2003) 163-168
38. Haakova L., Cibula D., Rezabek K., Hill M., Fanta M., and Zivny J. Pregnancy outcome in women with PCOS and in controls matched by age and weight. Hum Reprod 18 (2003) 1438-1441
39. Mikola M., Hiilesmaa V., Halttunen M., Suhonen L., and Tiitinen A. Obstetric outcome in women with polycystic ovarian syndrome. Hum Reprod 16 (2001) 226-229
40. Balen A.H., Conway G.S., Kaltsas G., Techatrasak K., Manning P.J., West C., et al. Polycystic ovary syndrome. the spectrum of the disorder in 1741 patients. Hum Reprod 10 (1995) 2107-2111
41. Elting M.W., Korsen T.J., Rekers-Mombarg L.T., and Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 15 (2000) 24-28
42. Dahlgren E., Johansson S., Lindstedt G., Knutsson F., Oden A., Janson P.O., et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965. a long-term follow-up focusing on natural history and circulating hormones. Fertil Steril 57 (1992) 505-513
43. Giorlandino C., Gleicher N., Taramanni C., Vizzone A., Gentili P., Mancuso S., et al. Ovarian development of the female child and adolescent: I. Morphology. Int J Gynaecol Obstet 29 (1989) 57-63
44. Rosenfield R.L., Ghai K., Ehrmann D.A., and Barnes R.B. Diagnosis of the polycystic ovary syndrome in adolescence. comparison of adolescent and adult hyperandrogenism. J Pediatr Endocrinol Metab 13 Suppl 5 (2000) 1285-1289
45. Balen A. Pathogenesis of polycystic ovary syndrome-the enigma unravels?. Lancet 354 (1999) 966-967
46. Adams J., Franks S., Polson D.W., Mason H.D., Abdulwahid N., Tucker M., et al. Multifollicular ovaries. clinical and endocrine features and response to pulsatile gonadotropin releasing hormone. Lancet 2 (1985) 1375-1379
47. Atiomo W.U., Pearson S., Shaw S., Prentice A., and Dubbins P. Ultrasound criteria in the diagnosis of polycystic ovary syndrome (PCOS). Ultrasound Med Biol 26 (2000) 977-980
48. Zawadzki J.K., and Dunaif A. Diagnostic criteria for polycystic ovary syndrome; towards a rational approach. In: Dunaif A., et al. (Ed). Polycystic Ovary Syndrome (1992), Blackwell Scientific Publications, Boston, MA 377-384
49. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 81 (2004) 19-25
50. Balen A.H., Laven J.S., Tan S.L., and Dewailly D. Ultrasound assessment of the polycystic ovary. international consensus definitions. Hum Reprod Update 9 (2003) 505-514
51. Christensen J.T., Boldsen J., and Westergaard J.G. Ovarian volume in gynecologically healthy women using no contraception, or using IUD or oral contraception. Acta Obstet Gynecol Scand 76 (1997) 784-789
52. Azziz R. Diagnostic criteria for polycystic ovary syndrome. a reappraisal. Fertil Steril 83 (2005) 1343-1346
53. Geisthovel F. A comment on the European Society of Human Reproduction and Embryology/American Society for Reproductive Medicine consensus of the polycystic ovarian syndrome. Reprod Biomed Online 7 (2003) 602-605
54. Hennekens C.H., Buring J.E., and Mayrent S.L. Epidemiology in medicine (1987), Little, Brown, Boston, MA
55. Rothman K.J., and Greenland S. Types of epidemiologic studies. Modern epidemiology (1998), Lippincott-Raven, Philadelphia, PA 67-91
56. Kleinbaum D.G., Kupper L.L., and Morgenstern H. Epidemiologic research principles and quantitative methods (1982), Lifetime Learning Publications, Belmont, CA
57. Szklo M., and Nieto F.J. Epidemiology beyond the basics (2004), Jones and Bartlett, Sudbury, MA
58. Hill A.B. The environment and disease. association or causation?. Proc R Soc Med 58 (1965) 295-300
59. Schlesselman J.J., and Stolley P.D. Case-control studies design, conduct, analysis (1982), Oxford University Press, New York, NY
60. Wacholder S., McLaughlin J.K., Silverman D.T., and Mandel J.S. Selection of controls in case-control studies. I. Principles. Am J Epidemiol 135 (1992) 1019-1028
61. Poole C. Controls who experienced hypothetical causal intermediates should not be excluded from case-control studies. Am J Epidemiol 150 (1999) 547-551
62. Miettinen O.S. The "case-control" study. valid selection of subjects. J Chronic Dis 38 (1985) 543-548
63. Rothman K.J., and Greenland S. Case-control studies. In: Rothman K.J., and Greenland S. (Eds). Modern epidemiology (1998), Lippincott-Raven, Philadelphia, PA 93-114
64. San Millan J.L., Botella-Carretero J.I., Varez-Blasco F., Luque-Ramirez M., Sancho J., Moghetti P., et al. A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11{beta}-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome. J Clin Endocrinol Metab 90 (2005) 4157-4162
65. Witchel S.F., Kahsar-Miller M., Aston C.E., White C., and Azziz R. Prevalence of CYP21 mutations and IRS1 variant among women with polycystic ovary syndrome and adrenal androgen excess. Fertil Steril 83 (2005) 371-375
66. Orio Jr. F., Palomba S., Spinelli L., Cascella T., Tauchmanova L., Zullo F., et al. The cardiovascular risk of young women with polycystic ovary syndrome. an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 89 (2004) 3696-3701
67. Walch K., Grimm C., Zeillinger R., Huber J.C., Nagele F., and Hefler L.A. A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome. Fertil Steril 81 (2004) 1638-1641
68. Schwartz S., and Link B.G. The "well control" artefact in case/control studies of specific psychiatric disorders. Psychol Med 19 (1989) 737-742
69. Selvin S. Statistical analysis of epidemiologic data (2004), Oxford University Press, New York, NY
70. Hernan M.A., Hernandez-Diaz S., and Robins J.M. A structural approach to selection bias. Epidemiology 15 (2004) 615-625
71. Pearl J. Causal diagrams for empirical research. Biometrika 82 (1995) 669-688
72. Greenland S. Quantifying biases in causal models. classical confounding vs. collider-stratification bias. Epidemiology 14 (2003) 300-306
73. Azziz R., Woods K.S., Reyna R., Key T.J., Knochenhauer E.S., and Yildiz B.O. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab 89 (2004) 2745-2749
74. Hatch R., Rosenfield R.L., Kim M.H., and Tredway D. Hirsutism. implications, etiology, and management. Am J Obstet Gynecol 140 (1981) 815-830
75. Michelmore K.F., Balen A.H., Dunger D.B., and Vessey M.P. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 51 (1999) 779-786
76. Adams J., Polson D.W., and Franks S. Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 293 (1986) 355-359
77. Azziz R., Sanchez L.A., Knochenhauer E.S., Moran C., Lazenby J., Stephens K.C., et al. Androgen excess in women. experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89 (2004) 453-462
78. Cornfield J. A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst 11 (1951) 1269-1275
79. Zhang J., and Yu K.F. What's the relative risk? A method of correcting the odds ratio in cohort studies of common outcomes. Journal of the American Medical Association 280 (1998) 1690-1691
80. Knochenhauer E.S., Key T.J., Kahsar-Miller M., Waggoner W., Boots L.R., and Azziz R. Prevalence of the polycystic ovary syndrome in unselected Black and White women of the southeastern United States. a prospective study. J Clin Endocrinol Metab 83 (1998) 3078-3082
81. Polson D.W., Adams J., Wadsworth J., and Franks S. Polycystic ovaries-a common finding in normal women. Lancet 1 (1988) 870-872
82. Rodin D.A., Bano G., Bland J.M., Taylor K., and Nussey S.S. Polycystic ovaries and associated metabolic abnormalities in Indian subcontinent Asian women. Clin Endocrinol (Oxf) 49 (1998) 91-99
83. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol 103 (1976) 226-235
84. Greenland S., and Thomas D.C. On the need for the rare disease assumption in case-control studies. Am J Epidemiol 116 (1982) 547-553
85. Prentice R.L., Kalbfleisch J.D., Peterson Jr. A.V., Flournoy N., Farewell V.T., and Breslow N.E. The analysis of failure times in the presence of competing risks. Biometrics 34 (1978) 541-554
86. Isojarvi J.I., Tauboll E., and Herzog A.G. Effect of antiepileptic drugs on reproductive endocrine function in individuals with epilepsy. CNS Drugs 19 (2005) 207-223